title: Revisiting the monoamine hypothesis of depression: a new perspective.
abstract: As the incidence of depression increases, depression continues to inflict additional suffering to individuals and societies and better therapies are needed. Based on magnetic resonance spectroscopy and laboratory findings, gamma aminobutyric acid (GABA) may be intimately involved in the pathophysiology of depression. The isoelectric point of GABA (pI = 7.3) closely approximates the pH of cerebral spinal fluid (CSF). This may not be a trivial observation as it may explain preliminary spectrophotometric, enzymatic, and HPLC data that monoamine oxidase (MAO) deaminates GABA. Although MAO is known to deaminate substrates such as catecholamines, indoleamines, and long chain aliphatic amines all of which contain a lipophilic moiety, there is very good evidence to predict that a low concentration of a very lipophilic microspecies of GABA is present when GABA pI = pH as in the CSF. Inhibiting deamination of this microspecies of GABA could explain the well-established successful treatment of refractory depression with MAO inhibitors (MAOI) when other antidepressants that target exclusively levels of monoamines fail. If further experimental work can confirm these preliminary findings, physicians may consider revisiting the use of MAOI for the treatment of non-intractable depression because the potential benefits of increasing GABA as well as the monoamines may outweigh the risks associated with MAOI therapy.
authors.affiliation: Durham Veterans Affairs Medical Center, Duke University School of Medicine, Durham, North Carolina, USA.
authors.forename: Joel S
authors.initials: JS
authors.lastname: Goldberg
authors.affiliation: Department of Chemistry, Winston-Salem State University, Winston-Salem, North Carolina, USA.
authors.forename: Clifton E
authors.initials: CE
authors.lastname: Bell
authors.affiliation: Department of Chemistry, Winston-Salem State University, Winston-Salem, North Carolina, USA.
authors.forename: David A
authors.initials: DA
authors.lastname: Pollard
keywords: GABA; depression; monoamine oxidase
references.citation: Perspect Medicin Chem. 2010 Aug 03;4:23-31
references.pmid: 20703328
references.citation: Gegenbaurs Morphol Jahrb. 1989;135(2):357-65
references.pmid: 2759416
references.citation: J Neurochem. 1985 May;44(5):1373-7
references.pmid: 3989535
references.citation: Arch Gen Psychiatry. 2004 Jul;61(7):705-13
references.pmid: 15237082
references.citation: Br J Anaesth. 2005 Oct;95(4):434-41
references.pmid: 16051647
references.citation: J Pharm Pharmacol. 1989 Mar;41(3):205-8
references.pmid: 2568453
references.citation: Eur Arch Psychiatry Clin Neurosci. 2006 Aug;256(5):268-73
references.pmid: 16927039
references.citation: CNS Spectr. 2005 Oct;10(10):808-19
references.pmid: 16400244
references.citation: Perspect Psychiatr Care. 1994 Oct-Dec;30(4):26-31
references.pmid: 7724340
references.citation: N Engl J Med. 1954 Dec 16;251(25):1006-8
references.pmid: 13214379
references.citation: J Clin Psychiatry. 2004 Nov;65(11):1520-4
references.pmid: 15554766
references.citation: Eur J Pharm Sci. 2011 Sep 18;44(1-2):68-73
references.pmid: 21726635
references.citation: Arch Gen Psychiatry. 2007 Feb;64(2):193-200
references.pmid: 17283286
references.citation: J Affect Disord. 1995 Dec 13;35(3):125-9
references.pmid: 8749840
references.citation: Depress Anxiety. 2009;26(3):279-88
references.pmid: 19031487
references.citation: J Clin Psychiatry. 2012;73 Suppl 1:17-24
references.pmid: 22951238
references.citation: J Clin Psychopharmacol. 1991 Apr;11(2):127-32
references.pmid: 2056139
references.citation: Biol Psychiatry. 2009 May 1;65(9):792-800
references.pmid: 19058788
references.citation: J Pharm Pharm Sci. 2008 May 16;11(2):14s-21s
references.pmid: 19203467